23 research outputs found
Dystrophin rescue needed to recover a correct location of nNOS and the return to a normalized RyR1 status in treated GRMD dogs
International audienc
Combined treatment GDF5 and AAV-microDystrophin for Duchenne Muscular Dystrophy
International audienc
Dystrophin rescue needed to recover a correct location of nNOS and the return to a normalized RyR1 status in treated GRMD dogs
International audienc
Recommended from our members
Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy
International audienceMyostatin regulates skeletal muscle size via the activin receptor IIB (ActRIIB). However, its effect on muscle energy metabolism and energy-dependent muscle function remains largely unexplored. This question needs to be solved urgently since various therapies for neuromuscular diseases based on blockade of ActRIIB signaling are being developed. Here, we show in mice, that 4-month pharmacological abrogation of ActRIIB signaling by treatment with soluble ActRIIB-Fc triggers extreme muscle fatigability. This is associated with elevated serum lactate levels and a severe metabolic myopathy in the mdx mouse, an animal model of Duchenne muscular dystrophy. Blockade of ActRIIB signaling downregulates porin, a crucial ADP/ATP shuttle between cytosol and mitochondrial matrix leading to a consecutive deficiency of oxidative phosphorylation as measured by in vivo Phosphorus Magnetic Resonance Spectroscopy ((31)P-MRS). Further, ActRIIB blockade reduces muscle capillarization, which further compounds the metabolic stress. We show that ActRIIB regulates key determinants of muscle metabolism, such as Pparbeta, Pgc1alpha, and Pdk4 thereby optimizing different components of muscle energy metabolism. In conclusion, ActRIIB signaling endows skeletal muscle with high oxidative capacity and low fatigability. The severe metabolic side effects following ActRIIB blockade caution against deploying this strategy, at least in isolation, for treatment of neuromuscular disorders
Phenotypic and genomic characterization as predictors of DMD 45 to 55 multi-exon skipping therapy
International audienceDuchenne and Becker muscular dystrophy (DMD and BMD) are X-linked myopathies characterized by a progressive muscular dystrophy with or without cardiomyopathy. As described in literature, 63% of DMD patients are eligible to a multi-exon skipping therapy, thus becoming BMD patients with exons 45 to 55 deletion (BMDdel45-55). Precision medicine approaches are currently in development and/or clinical testing. Interestingly, emerging regulatory actors as long non-coding RNA (lncRNA) are localized in 44 and 55 introns (Bovolenta et al., 2012). The specific neo-introns of each BMDdel45-55 patient could create or modify the lncRNA and/or RNA non-coding sequences and result in a various clinical outcome. Here we present a population of 54 "skip-equivalent" BMDdel45-55 patients. The objective is to identify modifier factors involved in phenotypic variability in these patients. We performed first a phenotypic characterization showing that 100% patients have BMD phenotype. Interestingly, 67% display the first signs age <16 y.o. The most disabling complains are the walking/running difficulties (65 %) and in 16 patients 50% have dilatative cardiomyopathy. Then we established the profile of lncRNA presence in 38/54 patients at genomic level in healthy subjects, muscle biopsies of BMDdel45-55 and DMD patients and human immortalized myoblasts displaying a deletion of 45-52 exons in DMD gene (Myo-45-52). We identified one cluster associating a smaller number of lncRNAs with a "milder" phenotype. In addition, in Myo-45-52 the profile of lncRNA expression underlined two lacking lncRNA. The WGS in 19/54 patients allowed precise identification of the deletion breakpoints underling specific sequence different for all analyzed patients. This study allowed us to describe phenotypic and genomic profile in the largest reported cohort of BMDdel45-55 patients. Genomic data profiling would have a favorable contribution in the design of these therapeutic approaches